Preclinical development of FL-091, a novel NTSR1 targeting radionuclide drug conjugate for the treatment of NTSR1-positive cancers

被引：0
|
作者：
Zhang, J. [1 ]
Yang, J. [1 ]
Liu, F. [1 ]
Wong, N. C. L. [1 ]
Thrane, K. T. [2 ]
Hallund, M. W. [2 ]
Gronlund, R. V. [2 ]
机构：
[1] Full Life Technol, Shanghai, Peoples R China
[2] Minerva Imaging ApS, Olstykke, Denmark
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2024年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP-676
引用
收藏
页码：S322 / S323
页数：2
相关论文
共 46 条
  • [21] Development of BT1718, a Bicycle Drug Conjugate (BDC) targeting MT1-MMP for treatment of solid tumours
    Bennett, G.
    Harrison, H.
    Campbell, S.
    Teufel, D.
    Langford, G.
    Watt, A.
    Bonny, C.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S21 - S21
  • [22] Characterization and preclinical development of STRO-001, a novel CD74-targeting antibody-drug conjugate (ADC) for the treatment of B-cell malignancies
    Abrahams, Cristina
    Li, Xiaofan
    DeAlmeida, Venita
    Embry, Millicent
    Yu, Abigail
    Krim, Stellanie
    Hoffmann, Heidi
    Zawada, James
    Bruhns, Maureen
    Matheny, Shannon
    Bussell, Stuart
    Kline, Toni
    Yam, Alice
    Stafford, Ryan
    Hallam, Trevor
    Lupher, Mark
    Molina, Arturo
    CANCER RESEARCH, 2017, 77
  • [23] SGN-LIV1A: a development stage antibody drug-conjugate targeting LIV-1 for the treatment of metastatic breast cancer.
    Sussman, Django
    Smith, Leia M.
    Anderson, Martha E.
    Duniho, Steve
    Hunter, Joshua H.
    Kostner, Heather
    Miyamoto, Jamie B.
    Nesterova, Albina
    Westendorf, Lori
    Van Epps, Heather A.
    Whiting, Nancy
    Benjamin, Dennis R.
    CANCER RESEARCH, 2013, 73 (08)
  • [24] Sudocetaxel Zendusortide (TH1902), a peptide-drug conjugate for the treatment of sortilin-positive (SORT1+) TNBC and Her2-positive breast cancers
    Charfi, Cyndia
    Demeule, Michel
    Currie, Jean-Christophe
    Zgheib, Alain
    Danalache, Bogdan Alexandru
    Beliveau, Richard
    Marsolais, Christian
    Annabi, Borhane
    CANCER RESEARCH, 2023, 83 (07)
  • [25] CLINICAL PHARMACOLOGY OF T-DM1: A NOVEL ANTIBODY-DRUG CONJUGATE (ADC) IN DEVELOPMENT FOR THE TREATMENT OF HER2-POSITIVE (HER2+) CANCER
    Girish, S.
    Gupta, M.
    Wang, B.
    Lu, D.
    Krop, I.
    Vogel, C.
    Burris, H.
    Yi, J.
    Saad, O.
    Tong, B.
    Klencke, B.
    Agresta, S.
    Chu, W.
    Joshi, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S12 - S12
  • [26] Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
    Sandhya Girish
    Manish Gupta
    Bei Wang
    Dan Lu
    Ian E. Krop
    Charles L. Vogel
    Howard A. Burris III
    Patricia M. LoRusso
    Joo-Hee Yi
    Ola Saad
    Barbara Tong
    Yu-Waye Chu
    Scott Holden
    Amita Joshi
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 1229 - 1240
  • [27] Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1
    Thomas, Lawrence J.
    Vitale, Laura
    O'Neill, Thomas
    Dolnick, Ree Y.
    Wallace, Paul K.
    Minderman, Hans
    Gergel, Lauren E.
    Forsberg, Eric M.
    Boyer, James M.
    Storey, James R.
    Pilsmaker, Catherine D.
    Hammond, Russell A.
    Widger, Jenifer
    Sundarapandiyan, Karuna
    Crocker, Andrea
    Marsh, Henry C., Jr.
    Keler, Tibor
    MOLECULAR CANCER THERAPEUTICS, 2016, 15 (12) : 2946 - 2954
  • [28] Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer
    Girish, Sandhya
    Gupta, Manish
    Wang, Bei
    Lu, Dan
    Krop, Ian E.
    Vogel, Charles L.
    Burris, Howard A., III
    LoRusso, Patricia M.
    Yi, Joo-Hee
    Saad, Ola
    Tong, Barbara
    Chu, Yu-Waye
    Holden, Scott
    Joshi, Amita
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (05) : 1229 - 1240
  • [29] A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers
    Coveler, Andrew L.
    Ko, Andrew H.
    Catenacci, Daniel V. T.
    Von Hoff, Daniel
    Becerra, Carlos
    Whiting, Nancy C.
    Yang, Jing
    Wolpin, Brian
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 319 - 328
  • [30] A novel pegylated bispecific antibody-drug conjugate (P-BsADCpb-adc) targeting cancers co-expressing PD-L1 and CD47
    Liu, Shumin
    Lyu, Weidong
    Yin, Shuqiang
    Lei, Yang
    Zhuo, Qiudong
    Zheng, Liling
    Sun, Bin
    Tan, Shuangyu
    Jiang, Lidong
    Zhang, Teng
    Gao, Bo
    Xu, Rui
    Huang, Dechang
    Li, Yong
    Wu, Zibin
    Wu, David
    Wen, Yvonne Yu
    CANCER RESEARCH, 2023, 83 (07)
12345